Revolution Medicines, Inc. provided earnings guidance for full year 2023. For the period, the company is projected full year 2023 GAAP net loss to be between $385 and $415 million, which includes estimated non-cash stock-based compensation expense of $45 million and $50 million. Based on the company?s current operating plan, the company projects current cash, cash equivalents and investments can fund planned operations into 2025.

The Company?s financial guidance excludes the financial impact of the proposed EQRx transaction.